KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Debt to Equity (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Debt to Equity for 6 consecutive years, with $0.02 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 2.87% to $0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.02 through Dec 2025, down 2.87% year-over-year, with the annual reading at $0.02 for FY2025, 2.87% down from the prior year.
  • Debt to Equity hit $0.02 in Q4 2025 for Castle Biosciences, down from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.05 in Q1 2022 to a low of $0.02 in Q4 2025.
  • Historically, Debt to Equity has averaged $0.03 across 3 years, with a median of $0.02 in 2024.
  • Biggest YoY gain for Debt to Equity was 2.87% in 2025; the steepest drop was 8.3% in 2025.
  • Year by year, Debt to Equity stood at $0.05 in 2022, then crashed by 58.1% to $0.02 in 2024, then decreased by 2.87% to $0.02 in 2025.
  • Business Quant data shows Debt to Equity for CSTL at $0.02 in Q4 2025, $0.02 in Q3 2025, and $0.02 in Q2 2025.